Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP news

Show

From To
Philippines trials anti-HIV drug as cases hit record high

The Philippines has kicked off a pilot project offering anti-HIV drugs to gays and transgender women as new infection rates in the country buck global trends and hit a record high.

Published
27 July 2017
From
Thomson Reuters
Rectal products for PrEP: Are they an option?

At the IAS 2017 conference this week, Ian McGowan, MD, PhD, FRCP, from University of Pittsburgh, discussed the need for (and challenges associated with) topical HIV prevention products, and a separate team of researchers presented promising findings from a very early study of a rectal HIV-prevention douche.

Published
27 July 2017
From
BETA blog
Update on PrEP Impact trial in England

In response to stakeholders, Public Health England (PHE) and NHS England have published an update on the PrEP Impact Trial.

Published
26 July 2017
From
Gov.uk
IPM receives award of up to $25 million From USAID to advance HIV prevention products for women

The award will expedite the potential licensure and market introduction of a new HIV prevention microbicide product for women, who continue to be disproportionately affected by the global HIV/AIDS epidemic.

Published
26 July 2017
From
Eurekalert Medicine & Health
Long-acting injectable cabotegravir for PrEP well tolerated in HPTN 077

Study results released today by the HIV Prevention Trials Network (HPTN) show long-acting injectable cabotegravir (CAB LA) to be well tolerated by men and women and support the dosing schedule currently being used in a phase 3 HPTN study for HIV prevention.

Published
25 July 2017
From
Eurekalert Inf Dis
IPM receives multi-year award from UK government to advance technologies for women's HIV

The nonprofit International Partnership for Microbicides (IPM) announced today that it has received a £12 million (US$15.6 million) award over four years from the United Kingdom government through the Department for International Development to advance promising HIV and multipurpose prevention products that women could use to protect their sexual and reproductive health.

Published
20 July 2017
From
Eurekalert Medicine & Health
Pre-exposure prophylaxis (PrEP) soon in Ukraine

The clients of the “ALLIANCE.GLOBAL”, PO will be the first in Ukraine to be able to use free pre-exposure prophylaxis of HIV infection (PrEP) already in 2017.

Published
20 July 2017
From
PO Alliance Global
Wales: Trial of 'game-changing' HIV drug gets underway

Trials of a drug to protect people against contracting HIV get underway this week in Wales. The drug, known as PrEP (pre-exposure prophylaxis) can be taken 'on demand' in order to protect against infection.

Published
19 July 2017
From
ITV News
The 2017 Pipeline Report

Treatment Action Group (TAG) announces the launch of its annual research and development landscape analysis: The Pipeline Report: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.

Published
19 July 2017
From
Treatment Action Group
PrEPARED in Wales

Information on getting PrEP from the NHS in Wales.

Published
18 July 2017
From
Frisky Wales
← First12345...90Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.